Phathom Pharmaceuticals Inc

NASDAQ:PHAT  
8.59
+0.44 (+5.40%)
Products

Phathom Pharmaceuticals Announces FDA Acceptance For Filing Of Vonoprazan NDA For Erosive Esophagitis Treatment

Published: 05/25/2022 12:16 GMT
Phathom Pharmaceuticals Inc (PHAT) - Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis.
Phathom Pharmaceuticals Inc - FDA Assigned Application Standard Review and a Prescription Drug User Fee Act (pdufa) Target Action Date of Jan 11, 2023.